Nové potenciání markery pro nádory prostaty a močového měchýře

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00006211" target="_blank" >RIV/61989592:15110/08:00006211 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of new potential tumor marker for urinary bladder cancer and prostate cancer

Popis výsledku v původním jazyce

pancreatic cancer tissues, in human breast cancer, gastric, cancer, lung cancer, ovary and colon cancer. No in formation was presented about prostata cancer (PC) a bladder cancer (BC). We evaluated periostin in peripheral blood as a potential biomarker for bladder and prostata gland cancer. Methods. Blood samples were used from 50 patients with urothelial tumors of the urinary bladder (BC), from 50 patients with prostata cancer (PC) and from 50 individuals with benign urological diseases. Blood was collected before cystoskopy and biopsy of prostata gland. Enzyme-linked immunosorbent assays (ELISA, Biovendor) were performed for periostin from serum. Simultaneously we measured serum and urine PSA (Immulite, Siemens), PSA free (Immulite, Siemens) and clusterin (ELISA, BioVendor). Results. Serum periostin were higher in individuals with PC (medians 59.7 vs. 47.6 ng/ml, P=0.73) but the difference was statistically insignificant. Similarly serum periostin did not differ in individuals with

Název v anglickém jazyce

Evaluation of new potential tumor marker for urinary bladder cancer and prostate cancer

Popis výsledku anglicky

pancreatic cancer tissues, in human breast cancer, gastric, cancer, lung cancer, ovary and colon cancer. No in formation was presented about prostata cancer (PC) a bladder cancer (BC). We evaluated periostin in peripheral blood as a potential biomarker for bladder and prostata gland cancer. Methods. Blood samples were used from 50 patients with urothelial tumors of the urinary bladder (BC), from 50 patients with prostata cancer (PC) and from 50 individuals with benign urological diseases. Blood was collected before cystoskopy and biopsy of prostata gland. Enzyme-linked immunosorbent assays (ELISA, Biovendor) were performed for periostin from serum. Simultaneously we measured serum and urine PSA (Immulite, Siemens), PSA free (Immulite, Siemens) and clusterin (ELISA, BioVendor). Results. Serum periostin were higher in individuals with PC (medians 59.7 vs. 47.6 ng/ml, P=0.73) but the difference was statistically insignificant. Similarly serum periostin did not differ in individuals with

Druh

A - Audiovizuální tvorba

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8399" target="_blank" >NR8399: Survivin a livin v diagnostice a dispezarizaci karcinomu močového měchýře z přechodného epitelu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

ISBN

—

Místo vydání

—

Název nakladatele resp. objednatele

Urologická klinika Olomouc

Verze

—

Identifikační číslo nosiče

—